Currently, Over 370 Agents are in Active Clinical Development, Addressing
Over 190 Targets
LAKE FOREST, Calif., Nov. 27 /PRNewswire/ -- Six ErbB (EGFr/HEr2)-pathway inhibitors, marketed for the treatment of several major solid tumor indications, generated global sales of $4,964.4 million in the first 9 months of 2007, almost surpassing the $5,160 million total revenues of these agents in 2006.
Despite this unprecedented market success and the acceptance of targeted therapies in oncology practice, many challenges remain unfulfilled. One key problem of currently approved agents is the relatively marginal benefits they provide; median progression-free survival (PFS) and overall survival (OS) are extended only by a few months. However, aggressive efforts to overcome current limitations are providing unique opportunities in this field.
Currently, all targeted therapeutics, both approved and novel are under evaluation almost exclusively in combination with approved cytotoxic agents. Because cytotoxics remain the treatment mainstay for adjuvant, neoadjuvant and advanced/metastatic disease, opportunities still exist for the development of more effective, less toxic alternatives.
Targeted therapeutics are also under investigation in combination with each other, in efforts to simultaneously inhibit additional or compensating pathways, or to maximize effectiveness against a single target by combining drugs acting by different mechanisms, e.g., receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies (MAb), against the same target. Also, multitargeted inhibitors are in development against different targets in the same or different pathways hypothesized to act in concert in malignancy.
The commercial success of the ErbB inhibitors and other targeted anticancer agents has stimulated R&D in this field. More than 370 drugs have entered clinical trials, with many having already reached phase II (n=183) or phase III (n=43) stages of development. In addition hundreds of agents are in preclinical development. Their mechanisms of action are wide ranging, targeting some of the more than 1,000 different molecular markers implicated in malignancy.
Molecularly targeted agents in development are ushering in the age of personalized medicine. There is pressing need for better diagnostic, theragnostic, prognostic, pharmacogenomic and disease monitoring methodologies for patient selection and optimized treatment.
The source, mechanisms of action, and preclinical and clinical status,
including interim and final trial results, of all of these agents are
described in detail in New Medicine's Oncology KnowledgeBASE (nm/OK). By
interrogating nm/OK users may:
-- Identify novel agents addressing either a single target or multiple
pathways/targets and review in detail their preclinical and clinical
-- Locate targeted agents in clinical trials in combination with specific
approved cytotoxic agents or classes of such drugs, i.e. platinum-based
agents, taxanes, etc.
-- Obtain comprehensive, cited data on over 1,000 targets that may be
applicable as diagnostic, theragnostic, prognostic, pharmacogenomic,
disease monitoring and/or therapeutic targets in cancer
-- Obtain interim and final results of combination trials of approved
anticancer agents, by cancer indication, target, clinical development
-- Obtain detailed records of anticancer targets by 100 different cancer
indications, and many subtypes such as non-small cell lung cancer
(nsclc), triple receptor-negative breast cancer, glioblastoma
multiforme (GBM), etc.
-- View detailed records of drugs in development for several hundred
highly specific clinical indications, i.e. advanced or metastatic
disease, adjuvant or neoadjuvant treatment, first line or second line
-- Obtain detailed preclinical and/or clinical pipelines of over 1,000
developers of anticancer agents, including detailed profiles of the
companies and their affiliates
-- Identify licensing opportunities
-- Assess global market opportunities based on revenues of approved drugs
and the epidemiology of specific cancer indications
-- Create proprietary 'saved searches' to monitor developments in a
pre-selected group of agents chosen by specific shared parameters,
i.e., targets, delivery systems, mechanism of action, cancer
indication, clinical indication, stage of development, etc.
Contact us for an on line demonstration of nm/OK.
Contact: Katie Siafaca
Tel: (949) 830-0448;
Fax: (949) 830-0887
|SOURCE New Medicine's Oncology KnowledgeBASE|
Copyright©2007 PR Newswire.
All rights reserved